The FX PostThe FX Post
    What's Hot

    Strong Ethereum Accumulation Detected: LTH Buying Heavy During June Consolidation | Ethereum Ethereum Accumulation | CryptoRank.io

    July 1, 2025

    Economic Calendar for the Week of June 29th

    June 30, 2025

    XRP jumps on Ripple-SEC update, Pomp scoops up $386M BTC: Hodler’s Digest, June 22 – 28

    June 29, 2025
    The FX Post The FX Post
    • Best Fx Robots
    • Forex
      • News
      • Forex 101
      • Forex Forecasts
      • Broker Reviews
    • Crypto
      • News
      • Crypto 101
      • Crypto Forecasts
      • Crypto Reviews
    • Indices
      • News
      • Analysis
      • Commodities
      • Reviews
    • Automated Trading
      • Forex Signals
      • Forex Robots
      • Copy Trading
    • Top
      • Best Forex Robots
    The FX PostThe FX Post
    Home ยป Ionis Pharmaceuticals Announces Partnership with Otsuka Pharmaceutical to Bring Donidalorsen Treatment to Europe
    News

    Ionis Pharmaceuticals Announces Partnership with Otsuka Pharmaceutical to Bring Donidalorsen Treatment to Europe

    December 18, 20232 Mins Read
    Facebook Twitter Pinterest LinkedIn Reddit
    Share
    Facebook Twitter LinkedIn Pinterest Reddit

    Ionis Pharmaceuticals has recently entered into a licensing agreement with Otsuka Pharmaceutical, aiming to utilize the latter’s established commercial infrastructure and extensive experience in rare disease drugs to provide the donidalorsen treatment to patients in Europe.

    Under this agreement, Ionis has granted exclusive rights to Otsuka for the commercialization of donidalorsen in Europe. Donidalorsen is an investigational preventative treatment designed for individuals suffering from hereditary angioedema, a rare genetic disorder characterized by abnormal fluid accumulation that leads to rapid swelling in various parts of the body including the hands, feet, limbs, face, intestines, or airways.

    While Ionis will continue to oversee the development of donidalorsen, Otsuka will spearhead the drug’s regulatory filings and commercialization efforts in European countries. As part of the deal, Ionis will receive an upfront payment of $65 million, along with potential milestone payments based on regulatory and sales targets. Additionally, Ionis will be eligible for royalties ranging from 20% to 30% of aggregate annual net sales.

    Dr. Brett Monia, the CEO of Ionis, expressed his satisfaction with the agreement, stating, “This partnership aligns perfectly with our strategy to initially focus on the U.S. market for commercialization efforts. We are highly encouraged by the impressive product profile of donidalorsen thus far, and we eagerly anticipate reporting pivotal Phase 3 results for the treatment of hereditary angioedema in the first half of next year.”

    Exciting two-year results from a Phase 2 trial were recently disclosed by Ionis, demonstrating that donidalorsen treatment resulted in an overall sustained mean reduction of 96% in hereditary angioedema attack rates when compared to baseline. Furthermore, the treatment has also obtained Orphan Drug Designation in the U.S., further highlighting its potential significance in addressing the needs of patients with this rare disorder.

    For inquiries or further information, please contact Ionis Pharmaceuticals at email.

    Markets are invaded by algorithms
    Secure your passive income with algo-based trading systems
    Learn more
    Donidalorsen Hereditary Angioedema Ionis Pharmaceuticals Otsuka Pharmaceutical Rare Disease Drugs
    Share. Facebook Twitter Pinterest LinkedIn Reddit

    Related Posts

    Strong Ethereum Accumulation Detected: LTH Buying Heavy During June Consolidation | Ethereum Ethereum Accumulation | CryptoRank.io

    July 1, 2025

    Economic Calendar for the Week of June 29th

    June 30, 2025

    XRP jumps on Ripple-SEC update, Pomp scoops up $386M BTC: Hodler’s Digest, June 22 – 28

    June 29, 2025

    Man charged in New York with 3-week kidnapping to try to steal Bitcoin

    May 30, 2025
    Add A Comment

    Leave A Reply Cancel Reply

    1  +  8  =  

    Best FX Post
    Best Forex Robots (Expert Advisors) 2021

    Best Forex Robots (Expert Advisors) 2022: Passive Income From Algo Trading Systems

    July 7, 2021

    Top 10 Lending Platforms for Crypto Loans

    June 1, 2022
    forex eurusd trading charts

    Top 10 Best Forex Brokers In All Times

    June 1, 2022
    Recent Posts
    • Strong Ethereum Accumulation Detected: LTH Buying Heavy During June Consolidation | Ethereum Ethereum Accumulation | CryptoRank.io
    • Economic Calendar for the Week of June 29th
    • XRP jumps on Ripple-SEC update, Pomp scoops up $386M BTC: Hodler’s Digest, June 22 – 28
    • Man charged in New York with 3-week kidnapping to try to steal Bitcoin
    • Goldman Sachs Expert Predicts Significant Gold Price Surge by 2026
    Featured Reviews

    Traders Connect Review

    May 18, 2023

    System Levels Review

    May 26, 2023
    TechBerry

    TechBerry Review: Pros, Cons, Recommendations

    September 18, 2021
    Categories
    • Analysis
    • Automated Trading
    • Best FX Post
    • Broker Reviews
    • Commodities
    • Copy Trading
    • Crypto
    • Crypto 101
    • Crypto Bots
    • Crypto Forecasts
    • Crypto Reviews
    • Crypto Robot
    • Forex
    • Forex 101
    • Forex Forecasts
    • Forex Robots
    • Forex Signals
    • Forex Signals
    • Guides
    • Indices
    • News
    • News
    • News
    • News
    • Reviews
    • Reviews
    • Uncategorized
    Twitter BlogLovin
    © 2025, Thefxpost.com.
    • Contact

    Type above and press Enter to search. Press Esc to cancel.